|

Camrelizumab Plus Chemotherapy and Famitinib Clinical Trials

1 actively recruiting trial

Also known as: camrelizumab+chemotherapy+Famitinib

Pipeline

Phase 3: 1

Top Sponsors

  • Fudan University1

Indications

  • TNBC - Triple-Negative Breast Cancer1
  • Breast Cancer1
  • Cancer1

Other1 trial

A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.